---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-064358"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T02:08:40.541370+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences Q4 net loss $9.9M, cash $302.2M; IND filings on track

## Summary
- Q4 2021 net loss $9.9M vs $3.7M; full-year net loss $26.3M vs $9.3M.
- Cash and cash equivalents $302.2M at year-end 2021; no revenue reported.
- IND for TYRA-300 (FGFR3) expected mid-2022; TYRA-200 (FGFR2) in H2 2022.
- Appointed Allison Kemner as VP Clinical Sciences and Operations in Q4 2021.
- Added to Russell 2000 Index in December 2021.

## SEC filing metadata
- accession: 0001193125-22-064358
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312522064358/0001193125-22-064358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312522064358/d265803d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-064358
- JSON: https://secwatch.observer/filing/0001193125-22-064358.json
- Plain text: https://secwatch.observer/filing/0001193125-22-064358.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.